Series: The Heart Scare That Almost Killed TRT
Subtitle: How a 2010 study, a flawed meta-analysis, and a media panic nearly derailed testosterone therapy for a generation
Post: 3 of 5
Tags: TRT, cardiovascular risk, low testosterone, hypogonadism, metabolic syndrome, observational studies, epidemiology
Word Count: ~1,100
Here is the quiet irony at the center of the 2013–2014 testosterone panic: while physicians were debating whether testosterone therapy was dangerous for the heart, there was a growing body of evidence suggesting that low testosterone itself — the condition being treated — was associated with elevated cardiovascular risk.
In other words, the debate was framed almost entirely around the risks of treatment. It was not framed, with nearly the same urgency, around the risks of non-treatment. And that asymmetry shaped policy in ways that arguably left men worse off.
The Pre-Existing Evidence
By 2010, when the Basaria trial was published and the alarm bells started ringing, researchers studying male hypogonadism had been accumulating observational data for years showing that low testosterone was not simply a cosmetic complaint. It was associated with a cluster of metabolic and cardiovascular abnormalities.
Several large cohort studies had demonstrated that men with hypogonadism had significantly higher rates of:
- Metabolic syndrome — the combination of central obesity, elevated triglycerides, low HDL cholesterol, elevated blood pressure, and elevated fasting glucose that dramatically increases cardiovascular risk
- Type 2 diabetes — with studies showing that testosterone deficiency was approximately twice as prevalent in men with T2DM as in matched controls
- All-cause mortality — multiple studies had found that men with lower testosterone levels died earlier, from a variety of causes, than men with higher levels
A 2006 paper by Dr. Elizabeth Barrett-Connor and colleagues, published in JAMA, followed a cohort of men in Rancho Bernardo, California, and found that men in the lowest quartile of bioavailable testosterone had a 38% higher all-cause mortality and a significantly higher cardiovascular mortality over an average 11.8 years of follow-up. This was not a study of TRT. It was a study of what happened to men who simply had low testosterone and didn’t treat it.
The Massachusetts Male Aging Study
The Massachusetts Male Aging Study (MMAS), which ran from 1987 to 2004 and followed a community sample of more than 1,700 men, provided some of the most influential observational data on the relationship between testosterone and metabolic health. The MMAS showed, among other findings, that low testosterone levels at baseline predicted the development of type 2 diabetes over the subsequent 10 years, with men in the lowest testosterone tertile having an approximately 42% greater risk of developing T2DM.
The MMAS also documented the relationship between testosterone and components of metabolic syndrome, showing that low total testosterone, low SHBG (sex hormone binding globulin), and high estradiol independently predicted the cluster of metabolic abnormalities that define the syndrome.
The Paradox Nobody Wanted to Discuss
The accumulation of this evidence created a genuinely uncomfortable intellectual position for critics of TRT. If low testosterone was associated with higher metabolic syndrome rates, higher diabetes rates, higher cardiovascular event rates, and higher mortality — and if there was biological plausibility for why this might be the case (testosterone promotes lean mass, reduces central adiposity, improves insulin sensitivity, reduces inflammatory markers) — then what exactly was the expected outcome of policies that discouraged treatment of documented testosterone deficiency?
The honest answer, in 2013, was: we didn’t know. The observational associations between low testosterone and cardiovascular risk did not prove that treating low testosterone with exogenous therapy would improve cardiovascular outcomes. Correlation is not causation. Testosterone levels might be low because men were metabolically compromised, rather than testosterone deficiency causing the metabolic compromise. The arrow of causality was not established.
This is fair. This is actually good scientific reasoning.
But here is where the framing mattered enormously: the 2010 Basaria study and the 2013 Vigen analysis were treated as though they were establishing that testosterone therapy caused cardiovascular harm. The observational studies showing that low testosterone was associated with cardiovascular harm were not treated with the same level of policy urgency. The FDA warning was about treatment. There was no corresponding FDA communication about the risks of undertreated hypogonadism.
The UK Biobank Data
More recent data from the UK Biobank — one of the largest prospective cohort studies ever conducted, with hundreds of thousands of participants followed over many years — has refined the picture considerably. A 2026 review by Yeap and Anawalt in the Journal of Clinical Endocrinology and Metabolism summarized the UK Biobank findings: in the Biobank data, lower endogenous testosterone concentrations were associated with higher risk of all-cause mortality, but the relationship with incident cardiovascular events or cardiovascular deaths was less clearly established in that particular dataset.
What did emerge clearly from the Biobank and from individual participant data meta-analyses of prospective cohort studies — where testosterone was measured using the gold standard of mass spectrometry rather than immunoassay — was a nonlinear pattern: cardiovascular mortality risk increased substantially when testosterone fell below approximately 5.3 nmol/L (153 ng/dL), and all-cause mortality risk increased below approximately 7.4 nmol/L (213 ng/dL). These are relatively low thresholds, but they identify a subgroup of men at meaningfully elevated risk.
Why the Framing Mattered for Policy
The policy implications of the bidirectional evidence were significant. A physician deciding whether to prescribe testosterone therapy to a symptomatic man with documented low testosterone and no prior cardiac events was, in 2014, operating under an FDA warning that foregrounded treatment risk. The countervailing evidence — that hypogonadism itself carried cardiovascular and metabolic risks — was available in the literature but was not given equal weight in the regulatory framing.
This is not to suggest that the FDA acted irresponsibly or that the concerns were manufactured. The concerns were real. Uncertainty is a legitimate basis for regulatory caution, and a proper randomized controlled trial was genuinely needed.
But the asymmetry — where treatment risk was formally communicated and the risks of the untreated condition were not — shaped clinical practice in ways that left real patients undertreated.
The analogy is imperfect but instructive: if a physician treating a diabetic patient were presented with an FDA warning about the cardiovascular risks of metformin, without a corresponding communication about the cardiovascular consequences of uncontrolled hyperglycemia, the prescribing calculus would be distorted in a systematic direction.
The field needed a definitive trial. And in the mid-2010s, the process of designing one was underway.
Next up: Post 4 — “The TRAVERSE Trial: 5,246 Men, 33 Months, and a New England Journal of Medicine Paper That Finally Settled the Cardiovascular Question.”
